代汉仁，博士，校聘教授，博士研究生导师，博士后合作导师
安徽医科大学“东南学者”。主持国家自然科学基金、中国博士后基金面上项目等多项课题研究，发表SCI论文6篇。主要从事细胞免疫治疗相关研究，代表性成果发表在Journal of Hepatology、Cytotherapy、J Natl Cancer Inst、Oncoimmunology、Nature Communications、J Hematol Oncol等学术期刊，其中一篇入选ESI高被引论文。
研究方向：细胞免疫治疗，炎症免疫性疾病。
联系方式：daihanren0321@126.com
主持课题：
1.国家自然科学基金面上项目，82270641，CAR修饰巨噬细胞靶向杀伤肝星状细胞治疗肝纤维化，2023/01-2026/12
2.国家自然科学基金青年基金项目，81602711，双靶向CD19/CD22嵌合抗原受体治疗急性B淋巴细胞白血病的应用基础研究，2017/01-2019/12
3.中国博士后科学基金第69批面上资助二等，2021M690186
部分发表文章：
1. Dai H†, Zhu C†, Huai Q, Xu W, Zhu J, Zhang X, Zhang X, Sun B, Xu H, Zheng M, Li X*, Wang H*. Chimeric antigen receptor-modified macrophages ameliorate liver fibrosis in preclinical models. Journal of Hepatology. 2024 Feb 8:S0168-8278(24)00113-2. .
2. Li X, Huai Q, Zhu C, Zhang X, Xu W, Dai H*, Wang H*. GDF15 ameliorates liver fibrosis by metabolic reprogramming of macrophages to acquire anti-inflammatory properties. Cellular and Molecular Gastroenterology and Hepatology. 2023;16(5):711-734.
3. Wang Y†, Tong C†, Dai H†, Wu Z†, Han X†, Guo Y, Chen D, Wei J, Ti D, Liu Z, Mei Q, Li X, Dong L, Nie J, Zhang Y, Han W. Low-dose decitabine priming endows CAR T cells with enhanced and persistent antitumour potential via epigenetic reprogramming. Nat Commun. 2021 Jan 18;12(1):409.
4. Dai H, Tong C, Shi D, Chen M, Guo Y, Chen D, Han X, Wang H, Wang Y, Shen P. Efficacy and biomarker analysis of CD133-directed CAR T cells in advanced hepatocellular carcinoma: a single-arm, open-label, phase II trial. Oncoimmunology. 2020 Nov 25;9(1):1846926.
5. Dai H†, Wu Z†, Jia H†, Tong C, Guo Y, Ti D, Han X, Liu Y, Zhang W, Wang C, Zhang Y, Chen M, Yang Q, Wang Y, Han W. Bispecific CAR-T cells targeting both CD19 and CD22 for therapy of adults with relapsed or refractory B cell acute lymphoblastic leukemia. J Hematol Oncol. 2020 Apr 3;13(1):30. (ESI高被引论文)
6. Dai H, Zhou Y, Tong C, Guo Y, Shi F, Wang Y*, Shen P*.Restoration of CD3+CD56+ cell level improves skin lesions in severe psoriasis: A pilot clinical study of adoptive immunotherapy for patients with psoriasis using autologous cytokine-induced killer cells. Cytotherapy. 2018 Sep;20(9):1155-1163
7. Zhang Y†, Zhang W†, Dai H†, Wang Y, Shi F, Wang C, Guo Y, Liu Y, Chen M, Feng K, Zhang Y, Liu C, Yang Q, Li S, Han W*. An analytical biomarker for treatment of patients with recurrent B-ALL after remission induced by infusion of anti-CD19 chimeric antigen receptor T (CAR-T) cells. Sci China Life Sci. 2016 Apr;59(4):379-85.
8. Feng K†, Guo Y†, Dai H†, Wang Y, Li X, Jia H, Han W*. Chimeric antigen receptor-modified T cells for the immunotherapy of patients with EGFR-expressing advanced relapsed/refractory non-small cell lung cancer. Sci China Life Sci. 2016 May;59(5):468-79.
9. Dai H†, Zhang W†, Li X†, Han Q†, Guo Y, Zhang Y, Wang Y, Wang C, Shi F, Zhang Y, Chen M, Feng K, Wang Q, Zhu H, Fu X, Li S*, Han W*. Tolerance and efficacy of autologous or donor-derived T cells expressing CD19 chimeric antigen receptors in adult B-ALL with extramedullary leukemia. Oncoimmunology. 2015; 4(11): e1027469.
10. Dai H†, Wang Y†, Lu X, Han W*. Chimeric Antigen Receptors Modified T-Cells for Cancer Therapy. J Natl Cancer Inst. 2016 Jan 27;108(7).